PriceTargets.com logo

Virpax Pharmaceuticals - VRPX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 809.09%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.33 As of 12/20/2024 06:51 PM ET
▲ +0.0136 (4.30%)

This chart shows the closing price for VRPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Virpax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRPX

Analyst Price Target is $3.00
▲ +809.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Virpax Pharmaceuticals in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 809.09% upside from the last price of $0.33.

This chart shows the closing price for VRPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Virpax Pharmaceuticals. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/9/2024Maxim GroupReiterated RatingBuy ➝ Hold
7/19/2024Maxim GroupUpgradeHold ➝ Buy$3.00
5/22/2024Maxim GroupReiterated RatingBuy ➝ Hold
6/9/2022Maxim GroupInitiated CoverageBuy$40.00
2/28/2022ThinkEquityInitiated CoverageBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Virpax Pharmaceuticals logo
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More

Today's Range

Now: $0.33
Low: $0.32
High: $0.37

50 Day Range

MA: $0.54
Low: $0.30
High: $0.76

52 Week Range

Now: $0.33
Low: $0.29
High: $5.48

Volume

970,033 shs

Average Volume

2,474,614 shs

Market Capitalization

$1.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Virpax Pharmaceuticals?

The following equities research analysts have issued reports on Virpax Pharmaceuticals in the last year: Maxim Group.
View the latest analyst ratings for VRPX.

What is the current price target for Virpax Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Virpax Pharmaceuticals in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 809.1%. Maxim Group has the highest price target set, predicting VRPX will reach $3.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Virpax Pharmaceuticals in the next year.
View the latest price targets for VRPX.

What is the current consensus analyst rating for Virpax Pharmaceuticals?

Virpax Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRPX, but not buy more shares or sell existing shares.
View the latest ratings for VRPX.

What other companies compete with Virpax Pharmaceuticals?

Other companies that are similar to Virpax Pharmaceuticals include Galecto, Trinity Biotech, Moleculin Biotech, ABVC BioPharma and Vincerx Pharma. Learn More about companies similar to Virpax Pharmaceuticals.

How do I contact Virpax Pharmaceuticals' investor relations team?

Virpax Pharmaceuticals' physical mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company's listed phone number is 610-727-4597 and its investor relations email address is [email protected]. The official website for Virpax Pharmaceuticals is www.virpaxpharma.com. Learn More about contacing Virpax Pharmaceuticals investor relations.